PDS Biotechnology Corp Business Acquisition, Pro Forma Earnings Per Share, Diluted
PDS Biotechnology Corp (PDSB) reported Business Acquisition, Pro Forma Earnings Per Share, Diluted of -$6.40 per share for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-18.
Discontinued › Income Statement › Earnings Per Share
us-gaap:BusinessAcquisitionProFormaEarningsPerShareDiluted · last filed 2021-03-18
- PDS Biotechnology Corp business acquisition, pro forma earnings per share, diluted for the quarter ending 2019-09-30 was -$3.15.
- PDS Biotechnology Corp business acquisition, pro forma earnings per share, diluted for the quarter ending 2019-06-30 was -$2.84.
- PDS Biotechnology Corp business acquisition, pro forma earnings per share, diluted for the quarter ending 2019-03-31 was -$4.19.
- PDS Biotechnology Corp business acquisition, pro forma earnings per share, diluted for the quarter ending 2018-09-30 was -$1.01.
- PDS Biotechnology Corp business acquisition, pro forma earnings per share, diluted for fiscal 2019 was -$6.40.
- PDS Biotechnology Corp business acquisition, pro forma earnings per share, diluted for fiscal 2018 was -$9.12.
| Period end | Business Acquisition, Pro Forma Earnings Per Share, Diluted 3 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 6 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 9 month | Business Acquisition, Pro Forma Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$6.40 10-K · filed 2021-03-18 | |||
| 2019-09-30 | -$3.15 10-Q · filed 2019-11-07 | -$2.88 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | -$2.84 10-Q · filed 2019-08-01 | -$4.44 10-Q · filed 2019-08-01 | ||
| 2019-03-31 | -$4.19 10-Q · filed 2019-05-14 | |||
| 2018-12-31 | -$9.12 10-K · filed 2020-03-27 | |||
| 2018-09-30 | -$1.01 10-Q · filed 2019-11-07 | -$8.28 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | -$2.70 10-Q · filed 2019-08-01 | -$7.37 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | -$4.64 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |